Featured News: Accent Presents Data on Lead Programs at AACR 2025 | Click to read the full press release

Accent Therapeutics Logo Accent Therapeutics Logo
  • APPROACH & PIPELINE
  • TEAM
  • NEWS & EVENTS
  • JOIN US

1050 Waltham St., Suite 201
Lexington, MA 02421
Tel: (339) 970-7400

  • LinkedIn
  • Twitter
Back to Team

Julie Hambleton, MD

Former CMO, IDEAYA Biosciences, Five Prime Therapeutics

Dr. Hambleton is a senior biotechnology executive with more than 20 years of experience in clinical drug development from pre-clinical through Phase 4 and post-marketing studies. She has extensive experience working with regulatory agencies, including the U.S. FDA and the European Medicines Agency (EMA), and in filings of Investigational New Drug Applications (INDs), Biologics License Applications (BLAs) and Special Protocol Assessments (SPAs). Dr. Hambleton served as interim President and Chief Executive Officer at Arch Oncology. Previously, she served as Senior Vice President, Chief Medical Officer and Head of Development at IDEAYA Biosciences, an oncology medicine company, until April 2020. Prior to her role at IDEAYA, she held the positions of Vice President, Head of U.S. Medical at Bristol-Myers Squibb, where she oversaw Medical & Health Economic and Outcomes Research activities in support of the Oncology, Immuno-Oncology, Specialty and Cardiovascular marketed portfolios; Executive Vice President and Chief Medical Officer at Five Prime Therapeutics; and Vice President, Clinical Development, at Clovis Oncology. Dr. Hambleton also serves on the board of directors of SpringWorks Therapeutics, and Erasca, Inc.

Julie Hambleton headshot
Wave shape
Accent therapeutics logo

1050 Waltham St., Suite 201
Lexington, MA 02421

Tel: (339) 970-7400
  • LinkedIn
  • Twitter

CONTACT US

For general inquiries:

contactus@accenttx.com

For partnership opportunities:

collaborations@accenttx.com

©2025 ACCENT THERAPEUTICS. All rights reserved.

  • Terms of Use
  • Privacy Policy